

Title: Trends in the Cumulative Post-Marketing Reporting Rates of Retinal Vasculitis and/or Retinal Vascular Occlusion and Associated Vision Loss with Brolucizumab

Authors: Franklin Igwe¹, Amit Lodha², Arun Ravindran³

Author Affiliations:

1. Novartis Pharma A.G., Basel, Switzerland.
2. Novartis Pharmaceuticals Corp., East Hanover, USA.
3. Novartis Healthcare Private Limited, Hyderabad, India.

Corresponding Author:

Franklin Igwe

Novartis Pharma A.G., Basel, Switzerland.

Tel : +41796376456

Email : franklin.igwe@novartis.com

Supplementary Material: The cumulative post-marketing reporting rates of RV and/or RO and associated vision loss per 10,000 injections are available in Table S1.

Table S1: Cumulative post-marketing reporting rates of RV and/or RO and associated vision loss per 10,000 injections

Date	Vision loss	RV	RO	RV and RO
08/05/2020	-	1.7	1.6	3.7
05/06/2020	-	2.0	2.5	4.2
26/06/2020	2.4	2.0	1.8	4.2
24/07/2020	3.1	2.7	2.6	4.8
28/08/2020	3.5	3.6	2.4	4.7
25/09/2020	4.9	4.5	3.0	6.1
23/10/2020	5.1	5.1	3.2	6.1
20/11/2020	5.6	5.1	3.2	7.2
18/12/2020	5.9	5.0	3.3	7.5
15/01/2021	5.9	4.5	3.4	7.4
12/02/2021	5.7	4.9	3.4	7.1
12/03/2021	5.5	5.1	3.4	7.2
09/04/2021	5.4	4.5	3.4	7.0
07/05/2021	5.3	4.9	3.2	7.4
04/06/2021	5.2	5.0	3.4	7.0
02/07/2021	5.0	5.0	3.4	7.2
30/07/2021	5.2	4.9	3.4	7.2
27/08/2021	4.9	5.1	3.0	7.0
24/09/2021	4.9	5.4	3.3	7.0
22/10/2021	4.8	5.6	3.2	6.7
19/11/2021	4.7	5.6	3.2	6.7

11/03/2022	4.7	5.6	3.3	6.6
03/06/2022	4.2	5.5	3.0	5.9
02/09/2022	4.1	5.6	3.1	5.5

RO, retinal vascular occlusion; RV, retinal vasculitis.